ENLV - CIK 0001596812
No parsed quarterly data available for Enlivex Therapeutics Ltd. yet.
Enlivex Therapeutics Ltd. reported operating cash flow of -$10.42M for fiscal year 2025. That is up 19.9% from -$13.01M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$15.49M (FY 2016) to -$10.42M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.